Cargando…
(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma
BACKGROUND: Bone disease in multiple myeloma is characterized by reduced bone formation. The gold standard of bone formation is the mineral apposition rate (MAR), an invasive technique reflecting bone formation at a single site. We compared (18)F-fluoride-PET with the MAR in myeloma patients. METHOD...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887457/ https://www.ncbi.nlm.nih.gov/pubmed/27246327 http://dx.doi.org/10.1186/s13550-016-0197-4 |
_version_ | 1782434727637024768 |
---|---|
author | Regelink, J. C. Raijmakers, P. G. Bravenboer, N. Milek, R. Hoetjes, N. J. de Kreuk, A. M. van Duin, M. Wondergem, M. J. Lips, P. Sonneveld, P. Zijlstra, J. M. Zweegman, S. |
author_facet | Regelink, J. C. Raijmakers, P. G. Bravenboer, N. Milek, R. Hoetjes, N. J. de Kreuk, A. M. van Duin, M. Wondergem, M. J. Lips, P. Sonneveld, P. Zijlstra, J. M. Zweegman, S. |
author_sort | Regelink, J. C. |
collection | PubMed |
description | BACKGROUND: Bone disease in multiple myeloma is characterized by reduced bone formation. The gold standard of bone formation is the mineral apposition rate (MAR), an invasive technique reflecting bone formation at a single site. We compared (18)F-fluoride-PET with the MAR in myeloma patients. METHODS: Bone formation was measured before and after bortezomib treatment by determination of the MAR in iliac bone marrow biopsies and the measurement of (18)F-uptake. RESULTS: The inter- and intra-individual variations in (18)F-uptake (SUV(A50%)) were pronounced as 33.50 (range 4.42 to 37.92) and 27.18 (range 4.00 to 31.18), respectively. A significant correlation between the MAR and (18)F-uptake was found (r = 0.80, p = 0.017). There was a heterogeneous response after treatment varying from −2.20 to 4.53. CONCLUSIONS: Iliac (18)F-uptake was associated with the local MAR in myeloma patients. Furthermore, (18)F-fluoride-PET demonstrated the heterogeneity of in vivo bone formation, enabling monitoring during treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13550-016-0197-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4887457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-48874572016-06-17 (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma Regelink, J. C. Raijmakers, P. G. Bravenboer, N. Milek, R. Hoetjes, N. J. de Kreuk, A. M. van Duin, M. Wondergem, M. J. Lips, P. Sonneveld, P. Zijlstra, J. M. Zweegman, S. EJNMMI Res Preliminary Research BACKGROUND: Bone disease in multiple myeloma is characterized by reduced bone formation. The gold standard of bone formation is the mineral apposition rate (MAR), an invasive technique reflecting bone formation at a single site. We compared (18)F-fluoride-PET with the MAR in myeloma patients. METHODS: Bone formation was measured before and after bortezomib treatment by determination of the MAR in iliac bone marrow biopsies and the measurement of (18)F-uptake. RESULTS: The inter- and intra-individual variations in (18)F-uptake (SUV(A50%)) were pronounced as 33.50 (range 4.42 to 37.92) and 27.18 (range 4.00 to 31.18), respectively. A significant correlation between the MAR and (18)F-uptake was found (r = 0.80, p = 0.017). There was a heterogeneous response after treatment varying from −2.20 to 4.53. CONCLUSIONS: Iliac (18)F-uptake was associated with the local MAR in myeloma patients. Furthermore, (18)F-fluoride-PET demonstrated the heterogeneity of in vivo bone formation, enabling monitoring during treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13550-016-0197-4) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-05-31 /pmc/articles/PMC4887457/ /pubmed/27246327 http://dx.doi.org/10.1186/s13550-016-0197-4 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Preliminary Research Regelink, J. C. Raijmakers, P. G. Bravenboer, N. Milek, R. Hoetjes, N. J. de Kreuk, A. M. van Duin, M. Wondergem, M. J. Lips, P. Sonneveld, P. Zijlstra, J. M. Zweegman, S. (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma |
title | (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma |
title_full | (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma |
title_fullStr | (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma |
title_full_unstemmed | (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma |
title_short | (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma |
title_sort | (18)f-fluoride-pet for dynamic in vivo monitoring of bone formation in multiple myeloma |
topic | Preliminary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887457/ https://www.ncbi.nlm.nih.gov/pubmed/27246327 http://dx.doi.org/10.1186/s13550-016-0197-4 |
work_keys_str_mv | AT regelinkjc 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma AT raijmakerspg 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma AT bravenboern 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma AT milekr 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma AT hoetjesnj 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma AT dekreukam 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma AT vanduinm 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma AT wondergemmj 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma AT lipsp 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma AT sonneveldp 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma AT zijlstrajm 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma AT zweegmans 18ffluoridepetfordynamicinvivomonitoringofboneformationinmultiplemyeloma |